What's new — Hypertensive heart disease¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 5 |
| last 2 months | 20 |
| last 3 months | 31 |
| last 6 months | 33 |
| last year | 41 |
| older than a year | 233 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-09 | 2026 ESC Guidelines for the management of heart failure — Eur Heart J ([PMID 42661420](https://pubmed.ncbi.nlm.nih.gov/42661420/){target="_blank" rel="noopener"}) | guidelines, heart-failure-management |
| 2026-10-07 | Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis — JAMA Cardiol ([PMID 42842238](https://pubmed.ncbi.nlm.nih.gov/42842238/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-10-06 | Baxdrostat in Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis — Cardiovasc Drugs Ther ([PMID 42837060](https://pubmed.ncbi.nlm.nih.gov/42837060/){target="_blank" rel="noopener"}) | pharmacologic-prevention-and-regression |
| 2026-10-05 | Systolic Blood Pressure Variability and Outcomes in Atrial Fibrillation: A Nationwide Population Study in Korea — J Korean Med Sci ([PMID 42843353](https://pubmed.ncbi.nlm.nih.gov/42843353/){target="_blank" rel="noopener"}) | arrhythmia-and-atrial-remodeling |
| 2026-10-05 | Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension: A Network Meta-Analysis of Randomized Trials — JACC Adv ([PMID 42832922](https://pubmed.ncbi.nlm.nih.gov/42832922/){target="_blank" rel="noopener"}) | pharmacologic-prevention-and-regression |
| 2026-10-01 | Large-scale plasma proteomic profiling enhances prediction of heart failure among hypertensive individuals: prospective insights from the UK Biobank — J Glob Health ([PMID 42895254](https://pubmed.ncbi.nlm.nih.gov/42895254/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers |
| 2026-10-01 | Blood pressure targets in adults with hypertension — Cochrane Database Syst Rev ([PMID 42861682](https://pubmed.ncbi.nlm.nih.gov/42861682/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-10-01 | Pulsed field ablation with Renal denervation for persistent Atrial fibrIllation: Rationale and design of the PRAISE-AF randomized trial — Am Heart J ([PMID 42860163](https://pubmed.ncbi.nlm.nih.gov/42860163/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-01 | Renal Sympathetic Denervation Plus Pulmonary Vein Isolation for Atrial Fibrillation in Patients with Hypertension: A Meta-Analysis of Randomised Controlled Trials — J Coll Physicians Surg Pak ([PMID 42851099](https://pubmed.ncbi.nlm.nih.gov/42851099/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-01 | Non-linear associations between blood pressure and clinical outcomes in atrial fibrillation: a systematic review and dose-response meta-analysis — Europace ([PMID 42663497](https://pubmed.ncbi.nlm.nih.gov/42663497/){target="_blank" rel="noopener"}) | arrhythmia-and-atrial-remodeling |
| 2026-09-06 | Cardiac MRI radiomics and texture analysis for differentiating the causes of left ventricular hypertrophy: a systematic review — Eur J Radiol ([PMID 42727224](https://pubmed.ncbi.nlm.nih.gov/42727224/){target="_blank" rel="noopener"}) | diagnosis-and-phenotyping |
| 2026-09-03 | Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023 — JAMA Cardiol ([PMID 42814432](https://pubmed.ncbi.nlm.nih.gov/42814432/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-02 | Baxdrostat (Baxfendy(®)), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension — Med Chem Res ([PMID 42809094](https://pubmed.ncbi.nlm.nih.gov/42809094/){target="_blank" rel="noopener"}) | pharmacologic-prevention-and-regression |
| 2026-09-02 | Blood pressure targets for hypertension in people with diabetes mellitus — Cochrane Database Syst Rev ([PMID 42788405](https://pubmed.ncbi.nlm.nih.gov/42788405/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-09-02 | Burden of non-communicable diseases and their attributable risk factors in Africa from 1990 to 2023: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet Glob Health ([PMID 42767254](https://pubmed.ncbi.nlm.nih.gov/42767254/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-01 | Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials — J Clin Hypertens (Greenwich) ([PMID 42757615](https://pubmed.ncbi.nlm.nih.gov/42757615/){target="_blank" rel="noopener"}) | pharmacologic-prevention-and-regression |
| 2026-09-01 | Metabolic syndrome severity and the effects of intensive blood pressure lowering: Results from the STEP randomized trial — Hypertens Res ([PMID 42749883](https://pubmed.ncbi.nlm.nih.gov/42749883/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-09-01 | Accelerating Burden of Hypertensive Heart Disease in Low- and Lower-Middle-SDI Countries, 1990-2023: The Contribution of Cold Temperature Exposure — Ann Glob Health ([PMID 42730369](https://pubmed.ncbi.nlm.nih.gov/42730369/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-01 | Prevalence of target organ damage in rural Kenya and The Gambia: a cross-sectional study — Lancet Reg Health Afr ([PMID 42729214](https://pubmed.ncbi.nlm.nih.gov/42729214/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-01 | Home blood pressure variability and risk of cardiovascular outcomes in elderly patients with non-valvular atrial fibrillation from the ANAFIE registry — Hypertens Res ([PMID 42722732](https://pubmed.ncbi.nlm.nih.gov/42722732/){target="_blank" rel="noopener"}) | arrhythmia-and-atrial-remodeling |
| 2026-08-24 | Reduced Blood Pressure Following Radiofrequency Renal Denervation in High Cardiovascular Risk Patients: The SPYRAL AFFIRM Study — JACC Cardiovasc Interv ([PMID 42637299](https://pubmed.ncbi.nlm.nih.gov/42637299/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-08-05 | Prediabetes, Malignant Left Ventricular Hypertrophy, and Risk of Incident Heart Failure Among Hypertensive Adults — JACC Adv ([PMID 42556210](https://pubmed.ncbi.nlm.nih.gov/42556210/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers |
| 2026-08-03 | Addressing systematic underdetection of left ventricular hypertrophy by guideline-recommended electrocardiographic criteria in women and individuals with overweight — Int J Cardiol ([PMID 42674294](https://pubmed.ncbi.nlm.nih.gov/42674294/){target="_blank" rel="noopener"}) | diagnosis-and-phenotyping |
| 2026-08-03 | Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study — Lancet ([PMID 42669305](https://pubmed.ncbi.nlm.nih.gov/42669305/){target="_blank" rel="noopener"}) | epidemiology-and-burden, heart-failure-management |
| 2026-08-03 | Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials — Eur J Heart Fail ([PMID 42669134](https://pubmed.ncbi.nlm.nih.gov/42669134/){target="_blank" rel="noopener"}) | diastolic-dysfunction-and-hfpef |
| 2026-08-02 | Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial — Circulation ([PMID 42666029](https://pubmed.ncbi.nlm.nih.gov/42666029/){target="_blank" rel="noopener"}) | lifestyle-and-population-prevention |
| 2026-08-02 | Hypertensive Crisis in the Elderly: Epidemiological, Clinical, and Outcome - EDEN-47 Study — Gerontology ([PMID 42664163](https://pubmed.ncbi.nlm.nih.gov/42664163/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-08-02 | Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy — JAMA ([PMID 42663420](https://pubmed.ncbi.nlm.nih.gov/42663420/){target="_blank" rel="noopener"}) | diagnosis-and-phenotyping |
| 2026-08-02 | Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study — Eur Heart J ([PMID 42663089](https://pubmed.ncbi.nlm.nih.gov/42663089/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers |
| 2026-08-02 | 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA) — Eur Heart J ([PMID 42661426](https://pubmed.ncbi.nlm.nih.gov/42661426/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-02 | Achieved home systolic blood pressure and cardiovascular risk in older hypertensive patients — Hypertens Res ([PMID 42660976](https://pubmed.ncbi.nlm.nih.gov/42660976/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-07-02 | 2026 ISH guidelines for the management of hypertension in Africa: the International Society of Hypertension (ISH) African Regional Advisory Group and the Pan African Society of Cardiology (PASCAR) — J Hypertens ([PMID 42554264](https://pubmed.ncbi.nlm.nih.gov/42554264/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-01 | Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia — BMC Cardiovasc Disord ([PMID 42321603](https://pubmed.ncbi.nlm.nih.gov/42321603/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-05-01 | Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications — Catheter Cardiovasc Interv ([PMID 42144689](https://pubmed.ncbi.nlm.nih.gov/42144689/){target="_blank" rel="noopener"}) | overview |
| 2026-04-01 | Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease — Clin Hypertens ([PMID 41953289](https://pubmed.ncbi.nlm.nih.gov/41953289/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers, diagnosis-and-phenotyping, outcomes-and-risk-stratification, overview |
| 2026-03-01 | Updates in the 2025 AHA/ACC Hypertension Guideline — Curr Hypertens Rep ([PMID 41843050](https://pubmed.ncbi.nlm.nih.gov/41843050/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-08 | Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study — Eur J Heart Fail ([PMID 41771092](https://pubmed.ncbi.nlm.nih.gov/41771092/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers, clinical-trials-landscape, diagnosis-and-phenotyping, guidelines, heart-failure-management, outcomes-and-risk-stratification, overview, patient-experience-and-advocacy |
| 2026-01-05 | Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment — Eur Heart J ([PMID 40892534](https://pubmed.ncbi.nlm.nih.gov/40892534/){target="_blank" rel="noopener"}) | diastolic-dysfunction-and-hfpef |
| 2025-12-05 | Systematic analysis of global ischemic heart disease and hypertensive heart disease burden, 1990-2021: projections to 2050 — BMC Public Health ([PMID 41350658](https://pubmed.ncbi.nlm.nih.gov/41350658/){target="_blank" rel="noopener"}) | epidemiology-and-burden, nosology-and-attribution |
| 2025-12-01 | A scoping review of qualitative studies examining the factors influencing hypertension treatment adherence in East Africa — J Biosoc Sci ([PMID 41414744](https://pubmed.ncbi.nlm.nih.gov/41414744/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-02 | Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study — PLOS Glob Public Health ([PMID 41270024](https://pubmed.ncbi.nlm.nih.gov/41270024/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
Trials — what has moved¶
25 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 2 |
| trial records updated in the last 2 months | 3 |
| trial records updated in the last 3 months | 4 |
| trial records updated in the last 6 months | 8 |
| trial records updated in the last year | 11 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-10-20 | Spyral InSight Study | NA | RECRUITING | 19 | clinical-trials-landscape |
| 2026-10-16 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With U | NA | ACTIVE_NOT_RECRUITING | 1899 | clinical-trials-landscape |
| 2026-09-24 | The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hy | NA | ACTIVE_NOT_RECRUITING | 224 | clinical-trials-landscape |
| 2026-08-26 | Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardia | NA | RECRUITING | 290 | clinical-trials-landscape |
| 2026-07-01 | Polyamine Treatment in Elderly Patients With Coronary Artery Disease | PHASE2 | COMPLETED | 187 | clinical-trials-landscape |
| 2026-06-24 | Mechanisms of LV Remodeling in Hypertensive Patients Working on a Rotational Expeditionary | NA | ACTIVE_NOT_RECRUITING | 550 | clinical-trials-landscape |
| 2026-06-17 | Baxdrostat and Ventricular Remodeling | PHASE3 | NOT_YET_RECRUITING | 286 | clinical-trials-landscape, pharmacologic-prevention-and-regression |
| 2026-05-29 | Renal Denervation Combined With Pulsed Field Ablation to Prevent Recurrence in Persistent | NA | ACTIVE_NOT_RECRUITING | 86 | clinical-trials-landscape |
| 2026-04-21 | A Study of the ReCor Medical Paradise System in Clinical Hypertension | NA | ACTIVE_NOT_RECRUITING | 282 | clinical-trials-landscape |
| 2026-04-15 | A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension ( | NA | ACTIVE_NOT_RECRUITING | 154 | clinical-trials-landscape |
| 2025-12-18 | China Rural Hypertension Control Project | NA | ACTIVE_NOT_RECRUITING | 33995 | lifestyle-and-population-prevention |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise S | NA | 224 | Change in Average Daytime Ambulatory Systolic BP | 14 | 126 | 0 |
| 2024-06-28 | A Study of the ReCor Medical Paradise System in Clinical Hypertension | NA | 282 | Solo Cohort - Mean Difference in Average Daytime Ambulatory Systolic B | 24 | 209 | 2 |
| 2021-05-27 | SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study | NA | 366 | Number of Participants With Major Adverse Events (MAE) Defined as a Co | 74 | 304 | 3 |
12 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| guidelines | 2026-10-09 | 5 | 29 |
| heart-failure-management | 2026-10-09 | 3 | 27 |
| blood-pressure-targets | 2026-10-07 | 5 | 30 |
| pharmacologic-prevention-and-regression | 2026-10-06 | 4 | 31 |
| arrhythmia-and-atrial-remodeling | 2026-10-05 | 3 | 28 |
| biomarkers-and-imaging-markers | 2026-10-01 | 5 | 28 |
| clinical-trials-landscape | 2026-10-01 | 4 | 28 |
| diagnosis-and-phenotyping | 2026-09-06 | 5 | 28 |
| epidemiology-and-burden | 2026-09-03 | 6 | 30 |
| diastolic-dysfunction-and-hfpef | 2026-08-03 | 2 | 26 |
| lifestyle-and-population-prevention | 2026-08-02 | 1 | 29 |
| red-flags-and-safety-concerns | 2026-08-02 | 1 | 27 |
| patient-experience-and-advocacy | 2026-06-01 | 4 | 26 |
| overview | 2026-05-01 | 3 | 38 |
| outcomes-and-risk-stratification | 2026-04-01 | 2 | 25 |
| nosology-and-attribution | 2025-12-05 | 1 | 25 |
| ventricular-remodeling | 2025-09-01 | 0 | 25 |
| secondary-hypertension-and-modifiers | 2025-08-07 | 0 | 26 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.